Dexcel Pharma Technologies Ltd. 13D and 13G filings for Protalix BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-06-15 09:19 am Sale |
2021-06-14 | 13G | Protalix BioTherapeutics, Inc. PLX |
Dexcel Pharma Technologies Ltd. | 2,034,117 4.470% |
-2,521,914 (-55.35%) |
Filing |
| 2021-02-16 12:06 pm Purchase |
2021-02-12 | 13G | Protalix BioTherapeutics, Inc. PLX |
Dexcel Pharma Technologies Ltd. | 4,556,031 10.300% |
1,267,940 (+38.56%) |
Filing |